Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic and Weight Loss Drugs
Journal of Clinical Medicine · 09.08.2024 · 13 (16) · 4674
DOI: 10.3390/jcm13164674 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 09.08.2024. Verfasst von Richard Le und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine and Public Health, Flinders University, Adelaide 5042, Australia. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 175 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Heart Foundation of Australia.
Abstract (Originalsprache)
Owing to their potent glucose-lowering efficacy and substantial weight loss effects, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now considered part of the frontline therapeutic options to treat both type 2 diabetes mellitus and nondiabetic overweight/obesity. Stemming from successful demonstration of their cardiometabolic modulation and reduction of major adverse cardiovascular events in clinical outcome trials, GLP-1 RAs have since been validated as agents with compelling cardiovascular protective properties. Studies spanning from the bench to preclinical and large-scale randomised controlled trials have consistently corroborated the cardiovascular benefits of this pharmacological class. Most notably, there is converging evidence that they exert favourable effects on atherosclerotic ischaemic endpoints, with preclinical data indicating that they may do so by directly modifying the burden and composition of atherosclerotic plaques. This narrative review examines the underlying pharmacology and clinical evidence behind the cardiovascular benefits of GLP-1 RAs, with particular focus on atherosclerotic cardiovascular disease. It also delves into the mechanisms that underpin their putative plaque-modifying actions, addresses existing knowledge gaps and therapeutic challenges and looks to future developments in the field, including the use of combination incretin agents for diabetes and weight loss management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Medicine and Public Health, Flinders University, Adelaide 5042, Australia.
- Heart and Vascular Program, Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide 5000, Australia.
- Department of Cardiology, Central Adelaide Local Health Network, Adelaide 5000, Australia.
- Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide 5005, Australia.
- Department of Endocrinology, Central Adelaide Local Health Network, Adelaide 5000, Australia.
ORCID-Profile: Richard Le, Jessica A Marathe
Förderung
- National Heart Foundation of Australia
Zitieren
APA
Le, R., Nguyen, M. T., Allahwala, M. A., Psaltis, J. P., Marathe, C. S., Marathe, J. A., & Psaltis, P. J. (2024). Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic and Weight Loss Drugs. Journal of Clinical Medicine, 13(16), 4674. https://doi.org/10.3390/jcm13164674
Vancouver
Le R, Nguyen MT, Allahwala MA, Psaltis JP, Marathe CS, Marathe JA, et al. Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic and Weight Loss Drugs. Journal of Clinical Medicine. 2024;13(16):4674. doi:10.3390/jcm13164674
BibTeX
@article{Le2024,
author = {Le, Richard and Nguyen, Mau T and Allahwala, Momina A and Psaltis, James P and Marathe, Chinmay S and Marathe, Jessica A and Psaltis, Peter J},
title = {Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic and Weight Loss Drugs},
journal = {Journal of Clinical Medicine},
year = {2024},
volume = {13},
number = {16},
pages = {4674},
doi = {10.3390/jcm13164674}
}
EUVIMED